SYRE · NASDAQ · STOCK
Spyre Therapeutics, Inc.
$102.72
52W $14.51 – $108.14
67/100
$8.92B
-52.7
3.03
Is SYRE Bullish or Bearish?
Mixed.
Innellis AI committee rates Spyre Therapeutics, Inc. (SYRE) Insufficient Data with a composite score of 67/100
, based on 3 analysts with 100% agreement.
Last updated August 11, 2026.
What Would Change This View
No threshold can be published for SYRE. The committee has not produced a scored recommendation, so there is no line for it to cross. Innellis does not infer one.
Executive Summary
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
67/100
Agreement
100%
Analysts
3
Conviction
Low Data
Sector Rank
Top 10%
of 192 Healthcare peers
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
53.3
Neutral
MACD Histogram
-0.189
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.65
Inside Bands
Price vs Moving Averages
EMA 9
$102.69
Above
EMA 21
$100.02
Above
EMA 50
$92.25
Above
EMA 200
$62.60
Above
Fundamental Analysis
Valuation
67
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-52.7×
P/B Ratio
7.91×
PEG Ratio
1.03
Dividend Yield
0.00%
52W High
$108.14
52W Low
$14.51
Quality & Growth
ROE
-2170.0%
ROA
-1995.5%
Gross Margin
0.0%
Operating Margin
-22249.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -52.7 (inexpensive relative to a 15-40x range); Price-to-book of 7.9x; PEG ratio of 1.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -21.7%; Return on assets of -20.0%; Net margin of -197.7%; Gross margin of 0.0%; Current ratio of 18.53 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-2.47); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full SYRE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →